PFK-015 is primarily used in research settings as a selective inhibitor of phosphofructokinase-1 (PFK-1), a key regulatory enzyme in the glycolytic pathway. Its main application lies in studying metabolic reprogramming in cancer cells, where altered glycolysis supports rapid tumor growth. By modulating PFK-1 activity, PFK-015 helps researchers investigate how glycolytic flux influences cell proliferation, survival, and response to therapeutic agents. It is also employed to explore the role of metabolism in immune cell activation and function, particularly in T cells, where glycolysis is crucial for effector responses. Due to its ability to shift metabolic pathways, PFK-015 serves as a tool compound in metabolic disease research, including diabetes and obesity, aiding in the understanding of glucose homeostasis and insulin sensitivity.